Rena Kaminsky

Special Counsel
Full contact info

Experience

Senti Biosciences Sells Certain Assets to Celadon Partners

August 14, 2023

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

Read more

Related contacts

Maureen Nagle
Special Counsel, Washington DC
Luke X. Blackett
Associate, San Francisco
Chrystal Cantrelle
Associate, Washington DC
Rena Kaminsky
Special Counsel, Palo Alto
Freddy Yip
Associate, Hong Kong
Peter Crain
Special Counsel, Reston
Alanna B Zuchelli
Associate, Reston
Ross Eberly
Partner, Los Angeles Santa Monica
Marya Postner
Partner, Palo Alto
Helen Luu
Associate, Palo Alto
Aric Wu
Partner, New York
Rachel Thorn
Partner, New York
Barbara Mirza
Partner, Los Angeles Santa Monica
Christopher Kimball
Partner, Washington DC
Dee Bansal
Partner, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Stacey A. Bradford
Special Counsel, Washington DC
J. Brian Stalter
Special Counsel, New York
Annie Froehlich
Special Counsel, Washington DC
Amanda Pacheco
Associate, Palo Alto
Zack Gong
Associate, Shanghai
Nicholas Balenger
Associate, Reston
Rachel Boyce
Associate, San Francisco
Ajay Athavale
Associate, San Francisco
Sarah Oliai
Associate, Washington DC
Leina Verrier
Associate, Los Angeles Santa Monica
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Neurocrine Biosciences Enters Collaboration Agreement with Sosei Heptares

November 23, 2021

We represented Neurocrine Biosciences in its strategic collaboration and licensing agreement with Sosei Heptares to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares in development for the treatment of major neurological disorders. Sosei Heptares received a total of $100 million in upfront cash and is eligible to receive up to approximately $1.5 billion related to the successful progression of licensed candidates through to regulatory approval. Sosei Heptares is also eligible to receive up to $1.1 billion upon achieving certain global sales milestones of any products developed under the partnership and is eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales.

Lawyers Kay Chandler and Rena Kaminsky led the Cooley team advising Neurocrine.

 

Related contacts

Kay Chandler
Partner, San Diego
Rena Kaminsky
Special Counsel, Palo Alto

Related Practices & Industries

Neurocrine Partners With Takeda to Address Psychiatric Disorders

June 30, 2020

Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.

Read more

Related contacts

Kay Chandler
Partner, San Diego
Rena Kaminsky
Special Counsel, Palo Alto
Jacqueline Grise
Partner, Washington DC
Megan Browdie
Partner, Washington DC
Jason Kent
Partner, New York
Carlos Ramirez
Partner, San Diego
Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto
Connie Tong
Patent Agent, Palo Alto
Natasha Leskovsek
Of Counsel, Washington DC
Stephanie Gentile
Partner, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Zai Lab Product Commercialization Collaboration with Regeneron

April 9, 2020

Cooley advised Zai Lab Limited, a China and U.S.-based innovative commercial stage biopharmaceutical company focused on developing medicines for cancer, infectious and autoimmune diseases to patients worldwide, on its global product commercialization collaboration with Regeneron Pharmaceuticals, Inc. This collaboration is focused on the development and commercialization of REGN1979, a bispecific antibody designed to treat lymphoma, in mainland China, Hong Kong, Taiwan, and Macau.

Related contacts

Lila Hope
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Rena Kaminsky
Special Counsel, Palo Alto

Related Practices & Industries

Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech

April 3, 2020

Fate Therapeutics in its global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Under the terms of the agreement, Janssen will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation  JJDC, Inc. of newly issued shares of the Company’s common stock at a price per share of $31.00. Janssen is also eligible to receive payments of up to  $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.

Related contacts

Lila Hope
Partner, Palo Alto
Rena Kaminsky
Special Counsel, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Robert Eisenbach
Of Counsel, San Francisco
Marc Suskin
Partner, New York
Natasha Leskovsek
Of Counsel, Washington DC

Related Practices & Industries

View more

Memberships & affiliations

American Bar Association